Stage Iv Nsclc clinical trials

Explore recruiting stage iv nsclc clinical trials.

Recruiting stage iv nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Stage Iv Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

Spain, Ireland, Poland, Belgium, France, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Combinatory ImmunoTherapy-2 (Com-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer

Norway

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non small Cell Lung Cancer (ARTEMIDE-01).

Belgium, Netherlands, Denmark, France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients

Belgium, France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A randomized, phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Stage Iv Nsclc trials by city

Stage Iv Nsclc in Toronto Stage Iv Nsclc in Vancouver Stage Iv Nsclc in Montreal Stage Iv Nsclc in Calgary Stage Iv Nsclc in Edmonton Stage Iv Nsclc in Ottawa Stage Iv Nsclc in Winnipeg Stage Iv Nsclc in Quebec City Stage Iv Nsclc in Hamilton Stage Iv Nsclc in Kitchener Stage Iv Nsclc in London Stage Iv Nsclc in Halifax Stage Iv Nsclc in New York Stage Iv Nsclc in Los Angeles Stage Iv Nsclc in Chicago Stage Iv Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease